523 related articles for article (PubMed ID: 10757381)
1. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
2. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
5. Hepatic neuroendocrine metastases: chemo- or bland embolization?
Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.
Kose E; Kahramangil B; Aydin H; Donmez M; Takahashi H; Aucejo F; Siperstein A; Berber E
Surg Endosc; 2020 Jan; 34(1):249-256. PubMed ID: 30945061
[TBL] [Abstract][Full Text] [Related]
7. 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases.
Ljungberg M; Westberg G; Vikhoff-Baaz B; Starck G; Wängberg B; Ekholm S; Ahlman H; Forssell-Aronsson E
Acta Radiol; 2012 Dec; 53(10):1118-26. PubMed ID: 23051638
[TBL] [Abstract][Full Text] [Related]
8. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
Hung JS; Chang MC; Lee PH; Tien YW
World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
[TBL] [Abstract][Full Text] [Related]
9. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?
Chen H; Hardacre JM; Uzar A; Cameron JL; Choti MA
J Am Coll Surg; 1998 Jul; 187(1):88-92; discussion 92-3. PubMed ID: 9660030
[TBL] [Abstract][Full Text] [Related]
10. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.
Sofocleous CT; Petre EN; Gonen M; Reidy-Lagunes D; Ip IK; Alago W; Covey AM; Erinjeri JP; Brody LA; Maybody M; Thornton RH; Solomon SB; Getrajdman GI; Brown KT
J Vasc Interv Radiol; 2014 Jan; 25(1):22-30; quiz 31. PubMed ID: 24365504
[TBL] [Abstract][Full Text] [Related]
13. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Strosberg JR; Choi J; Cantor AB; Kvols LK
Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of liver metastases from gastrointestinal endocrine tumors.
Boleslawski E; Dharancy S; Truant S; Pruvot FR
Gastroenterol Clin Biol; 2010; 34(4-5):274-82. PubMed ID: 20347242
[TBL] [Abstract][Full Text] [Related]
15. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
[TBL] [Abstract][Full Text] [Related]
16. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery.
Jaeck D; Oussoultzoglou E; Bachellier P; Lemarque P; Weber JC; Nakano H; Wolf P
World J Surg; 2001 Jun; 25(6):689-92. PubMed ID: 11376398
[TBL] [Abstract][Full Text] [Related]
17. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.
Lang H; Schlitt HJ; Schmidt H; Flemming P; Nashan B; Scheumann GF; Oldhafer KJ; Manns MP; Raab R
Langenbecks Arch Surg; 1999 Aug; 384(4):370-7. PubMed ID: 10473858
[TBL] [Abstract][Full Text] [Related]
18. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
19. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
20. Treatment of liver metastases in patients with neuroendocrine tumors.
Frilling A; Rogiers X; Malagó M; Liedke OM; Kaun M; Broelsch CE
Langenbecks Arch Surg; 1998 Mar; 383(1):62-70. PubMed ID: 9627173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
